Clinical Trial Update: A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic and safety study evaluated single and multiple doses of rabreprazole in children aged 1 to 11 with gastroesophageal reflux disease; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Rabreprazole (rabreprazole)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: GERD | Phase 1 | Status: COMPLETED